REPORT-HF: a heart failure disease registry
Research type
Research Study
Full title
International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF)
IRAS ID
156955
Contact name
Nataliya Kemenyash
Contact email
Sponsor organisation
Novartis Pharma AG
Duration of Study in the UK
6 years, 0 months, 0 days
Research summary
The main purpose of this observational REPORT-HF registry study is to learn more about patients condition and to observe the current medical care for patients with heart failure (HF) in different countries worldwide. Participation in the REPORT-HF registry starts with the initial hospitalisation, and continues with an observational period of three (3) years as there is limited information from previous registries on long-term follow-up. In addition to the long-term data collection, the study will also link treatment plans and clinical outcomes, to identify best practice in the Heart failure treatment, as well as extent of healthcare resources use. This registry will also collect data on health-related quality of life as well as economic and caregiver burden. The combination of extent of health resource use with the caregiver burden will enable a more comprehensive outline of the social burden of HF beyond the clinical outcomes.
It is planned to enroll approximately 20,000 patients at the time when they are hospitalised for an episode of heart failure. The regions participating include Asia, North-Central-and South America, Europe, Africa, Middle East, and Australia.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
14/SW/1042
Date of REC Opinion
31 Jul 2014
REC opinion
Further Information Favourable Opinion